Amgen’s Repatha Patent Challenge Continues
Amgen’s five-year legal challenge against Sanofi and Regeneron’s competitor for its cholesterol-lowering drug Repatha (evolocumab) is set to continue next month in a Delaware federal court.
Sanofi and Regeneron have filed a new motion in the U.S. District Court for Delaware challenging the Repatha patents as invalid and a hearing has been scheduled for Aug. 8.
The three companies are also awaiting the outcome of an injunction hearing held last month in which Amgen sought to block alleged infringement of the two Repatha patents by Sanofi and Regeneron’s competing drug Praluent (alirocumab).
On July 11, Amgen won an injunction against Praluent in a German court and the company’s attorneys have referenced that injunction in their U.S. court filing.